Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nuvelo(NUVO) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (56)	1/5/2006 9:00:14 PM
From: FiloF	Read Replies (1) \| Respond to of 140

Congrats from me too, TD. Your posts put this one on my radar screen and I never got around to looking at it closely. My loss. I assume it is not too late to hop on the bandwagon, though, huh?

To: Arthur Radley who wrote (56)	1/6/2006 7:35:19 PM
From: dr.praveen	Read Replies (2) \| Respond to of 140

Hi TD, Congrats on Nuvo. I used to own it an year ago and don't follow it now. This is Dew's post on Nuvo from I hub board. I would like to listen to your views and comments on it. TIA, Dr.P investorshub.com NUVO-Bayer post-mortem: The euphoria over the Bayer deal for Alfimeprase appears to be dying down now, after a 40% spike yesterday. I think the euphoria is not fully justified because the deal NUVO just struck with Bayer is not all that different in its aggregate economics from the arrangement that NUVO had with AMGN before AMGN pulled out in late 2004. Moreover, NUVO will still pay AMGN a royalty on Alfimeprase sales in all territories, which must be subtracted from NUVO’s ex-U.S. royalty received from Bayer in order to arrive at a net royalty for NUVO. This is not to say that the Bayer deal wasn’t a good one for NUVO—it was. I just don’t think it was the blowout, knock your socks off kind of deal that some observers seem to think it was.